Adagene (FRA:978) Total Long-Term Assets : €2.10 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Adagene Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Adagene's Total Long-Term Assets for the quarter that ended in Dec. 2023 was €2.10 Mil.

Adagene Total Long-Term Assets Historical Data

The historical data trend for Adagene's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Total Long-Term Assets Chart

Adagene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Assets

Get a 7-Day Free Trial

1.77

4.25

3.15

2.91

2.10

Adagene Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Long-Term Assets	Get a 7-Day Free Trial					3.15	3.35	2.91	2.42	2.10

Adagene Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Adagene Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Adagene's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Adagene (FRA:978) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (FRA:978) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

ADAG:USA 978:Germany

Address

Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123

Website

https://www.adagene.com

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Adagene (FRA:978) Headlines

No Headlines